Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘BIRCH trial’

Vienna, Austria: it’s day 2 of the European Cancer Congress in Vienna (Twitter #ECC2015).European Cancer Congress Vienna

Along with 18,000+ attendees we’re looking forward to hearing about some more practice changing data.

Today in Vienna brings another busy and jam packed day at the European Cancer Conference (ECC).  We’ve already reached the point where the days blur and you have no idea which day of the week it actually is, you just follow the next fresh day in your personalised program or schedule.

So what’s in store today?

This morning brings updates on lung cancer, including the much anticipated atezolizumab results in POPLAR and BIRCH, as well as urothelial bladder cancer from the IMVigor trial. There is also a melanoma session that includes the oncolytic virus T-VEC, together with pembrolizunab and cobimetinib in separate study readouts. All this before lunch!

The afternoon promises to be equally interesting with an Immunotherapy in Cancer session that includes nivolumab, pembrolizumab plus we get our first look at a novel immunocytokine targeting CEA-IL2. A parallel session explores the science behind brain tumours with presentations on the tumour microenvironment, biomarkers and current trials.

In the meantime, the embargoes lift at 7am CEST on several studies including the atezolizumab data, which we highlight here.

To learn more about our insights throughout the day, including the latest immuno-oncology perspectives – some of which is potentially practice changing – subscribers can log-in or you can sign up in the box below.

A decade or so ago, the annual conferences for the European Congress of Clinical Oncologists (ECCO) and European Society of Medical Oncologists (ESMO) were considered convenient dumping grounds for negative or failed trials. This was largely because they received much less attention than their big brother, the American Society of Clinical Oncology (ASCO).

In the last few years, this trend has shifted with excellent clincial and scientific data being presented at both meetings – they alternate as hosts each year – under the European Cancer Congress (ECC) umbrella.

Just to confuse a global audience long used to referring to the meetings as ESMO and ECCO, while the logical Twitter hashtag might appear to be #ESMO14 and #ECCO15, respectively, based on the standard nomenclature of conference acronym followed by the year, the vagaries of European politics mean we end up with… #ECC2015.

It will be interesting to see how they compete for attention because this hashtag signal will be dirty (more than one usage) and noisy (many disparate voices) with the European Curling Championship, a European Cheerleader Convention and another on e-cigarettes and vaping, all seemingly using the same moniker!

ECCO 2015 Vienna

Still, what many readers are really eager to learn though, is this a great, middling, or poor year for exciting new data in the field of cancer research and what can we expect to hear about in Vienna later this month?

To learn about what to expect, subscribers can log in or you can sign up in the box below to find out more…

error: Content is protected !!